How Far Are We from Prescribing Fasting as Anticancer Medicine?
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical mechanisms and preliminary clinical data with no systematic review or meta-analysis.
PubMed 33271979 · doi:10.3390/ijms21239175
What was done
This narrative review synthesized preclinical and clinical literature examining fasting as an adjuvant strategy to cancer chemotherapy. The authors reviewed hormonal, molecular, and cellular responses to fasting—specifically differential stress resistance and oxidative stress pathways—and discussed translational challenges including patient selection, fasting protocols, refeeding schedules, and biomarker validation.
What was found
The abstract reports no quantitative data or specific numerical endpoints. Preclinical evidence indicates that fasting reduces chemotherapy toxicity and enhances treatment efficacy by protecting normal cells while promoting cancer cell death. Human clinical research is described as encouraging but still in its infancy, requiring protocol standardization and safety confirmation.
Why it matters
The paper synthesizes the mechanistic rationale and outlines the clinical challenges that must be addressed before fasting can be routinely prescribed alongside standard oncological therapies.
Limits
As a narrative review, it lacks systematic search methodology and formal risk-of-bias assessment. Human clinical evidence remains preliminary, and the abstract reports no specific sample sizes, trial outcomes, or effect sizes.
Cited by
- partial Fasting selectively kills cancer cells because normal cells adapt to resource deprivation while cancer cells cannot.